-
公开(公告)号:US20210327536A1
公开(公告)日:2021-10-21
申请号:US17304940
申请日:2021-06-28
申请人: TEMPUS LABS, INC.
发明人: Ariane Lozac'hmeur , Jason Perera
摘要: Processes are provided for detecting loss of heterozygosity of Human Leukocyte Antigen (HLA) in a subject using analysis of next generation sequencing (NGS) data. The processes include aligning NGS data and identifying unmapped and mapped reads, updating reference data, and feeding one or more sequence reads to an HLA typing process for identifying candidate HLA alleles and feeding HLA type data to a loss of heterozygosity (LOH) modeling process for determining a LOH status for each HLA allele. A report may be generated of the LOH statuses for each of HLA allele.
-
52.
公开(公告)号:US20210319908A1
公开(公告)日:2021-10-14
申请号:US17356738
申请日:2021-06-24
申请人: Tempus Labs, Inc.
发明人: Hailey Lefkofsky , Ashraf Hafez , Julian Habib , Carin Fishel , Caroline Epstein
IPC分类号: G16H50/70 , G16H50/20 , G06N20/00 , G06K9/62 , G06F17/18 , G06N5/00 , G16H10/60 , G16H30/00 , G16H80/00 , G06F21/60 , G06F21/62
摘要: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.
-
公开(公告)号:US20210151192A1
公开(公告)日:2021-05-20
申请号:US17157974
申请日:2021-01-25
申请人: Tempus Labs, Inc.
发明人: Michael Ryan Lucas , Jonathan Ozeran , Jason L. Taylor , Louis E. Fernandes , Daniel Neems , Hunter Lane , Eric Lefkofsky
摘要: A system, method, and mobile device application are configured to capture, with a mobile device, a document such as a next generation sequencing (NGS) report that includes NGS medical information about a genetically sequenced patient. The method includes receiving, from a mobile device, an image of a medical document comprising NGS medical information of the patient, extracting a first region from the image, extracting NGS medical information of the patient from the first region into a structured dataset, the extracted NGS medical information including at least one RNA expression, correlating a portion of the extracted NGS medical information that includes the at least one RNA expression with summarized medical information from a cohort of patients similar to the patient, and generating, for display on the mobile device, a clinical decision support report comprising the summarized medical information.
-
公开(公告)号:US20210118559A1
公开(公告)日:2021-04-22
申请号:US17076801
申请日:2020-10-21
申请人: Tempus Labs, Inc.
发明人: Eric Lefkofsky
IPC分类号: G16H40/20 , G16H10/40 , G16H30/20 , G16H30/40 , G16H50/20 , G16H15/00 , G16H50/70 , A61B6/03 , G16B15/30
摘要: A system and method, the method comprising receiving a laboratory diagnostic testing result associated with a specimen of a subject, the steps of receiving a clinomic profile of the subject, identifying a cohort of similar subjects based at least in part on the clinomic profile of the subject, providing the diagnostic testing results, clinomic profile, and the cohort of similar subjects to a smart output module to generate a personalized, precision medicine based laboratory diagnostic testing result as a smart output and displaying the smart output to a user.
-
公开(公告)号:US20210115511A1
公开(公告)日:2021-04-22
申请号:US17076704
申请日:2020-10-21
申请人: Tempus Labs, Inc.
发明人: Richard Blidner
IPC分类号: C12Q1/6874 , C12Q1/6883
摘要: Systems and methods are provided for determining an optimized probe set. The method proceeds by obtaining a set of probes, where each probe has a respective concentration. The set of probes is assayed against a sample library, and at least i) a respective recovery rate for each probe in the set of probes, and ii) a median recovery rate for the set of probes are obtained. Modify the respective concentration of each probe that does not satisfy predetermined recovery rate threshold. Reevaluate the set of probes against the sample library. Repeat the modifying and reevaluation until the respective updated recovery rate for each probe in the updated set of probes satisfies the predetermined recovery rate threshold, thereby providing the optimized set of probes for the sample library.
-
公开(公告)号:US10975445B2
公开(公告)日:2021-04-13
申请号:US16789363
申请日:2020-02-12
申请人: Tempus Labs, Inc.
发明人: Aarti Venkat , Jerod Parsons , Joshua S K Bell , Catherine Igartua , Yilin Zhang , Ameen Salahudeen , Verónica Sánchez Freire , Robert Tell
摘要: Methods, systems, and software are provided for determining a homologous recombination pathway status of a cancer in a test subject, e.g., to improve cancer treatment predictions and outcomes. In some embodiments, classifiers using one or more of (i) a heterozygosity status for DNA damage repair genes in a cancerous tissue, (ii) a measure of the loss of heterozygosity across the genome of the cancerous tissue, (iii) a measure of variant alleles detected in a second plurality of DNA damage repair genes in the genome of the cancerous tissue, (iv) a measure of variant alleles detected in the second plurality of DNA damage repair genes in the genome of a non-cancerous tissue, and (v) tumor sample purity are provided.
-
公开(公告)号:US10957041B2
公开(公告)日:2021-03-23
申请号:US16830186
申请日:2020-03-25
申请人: TEMPUS LABS, INC.
发明人: Stephen Yip , Irvin Ho , Lingdao Sha , Boleslaw Osinski , Aly Azeem Khan , Andrew J. Kruger , Michael Carlson , Abel Greenwald , Caleb Willis
摘要: A generalizable and interpretable deep learning model for predicting biomarker status and biomarker metrics from histopathology slide images is provided.
-
58.
公开(公告)号:US20210057071A1
公开(公告)日:2021-02-25
申请号:US17001673
申请日:2020-08-24
申请人: Tempus Labs, Inc.
发明人: Mathew Barber , Ryan Mork
摘要: In one aspect, the present disclosure provides a method for labeling one or more medications concurrently administered to a patient as a line of therapy. The method includes identifying medical records of the patient from a plurality of digital records, creating, from the subset of medical records, a plurality of treatment intervals including at least one medication administered to the patient and a time interval, associating medications of the one or more treatments with a respective treatment interval when the administration of the medication falls within the time interval, refining the time interval of a respective treatment interval when a treatment of the one or more treatments falls outside the time interval but within an extension period, identifying one or more potential lines of therapy from the plurality of treatment intervals, and labeling the potential line of therapy having the highest maximum likelihood estimation as the line of therapy.
-
公开(公告)号:US20200258223A1
公开(公告)日:2020-08-13
申请号:US16830186
申请日:2020-03-25
申请人: TEMPUS LABS, INC.
发明人: Stephen Yip , Irvin Ho , Lingdao Sha , Boleslaw Osinski , Aly Azeem Khan , Andrew J. Kruger , Michael Carlson , Abel Greenwald , Caleb Willis
摘要: A generalizable and interpretable deep learning model for predicting biomarker status and biomarker metrics from histopathology slide images is provided.
-
公开(公告)号:US20200211189A1
公开(公告)日:2020-07-02
申请号:US16732242
申请日:2019-12-31
申请人: TEMPUS LABS, INC.
发明人: Stephen Yip , Irvin Ho , Lingdao Sha , Boleslaw Osinski
摘要: Techniques for generating an overlay map on a digital medical image of a slide are provided, and include cell detection and tissue classification processes. Techniques include receiving a medical image, separating the image into tiles, and performing tile classifications and tissue classifications based on a multi-tile analysis. Techniques additionally include identifying cell objects in the image, separating the image into and displaying polygons identifying the cell objects and cell classifications. Generated displays may be overlays over the initial digital image.
-
-
-
-
-
-
-
-
-